
Sign up to save your podcasts
Or


In this episode of The First Fill, we will review two recent new drug approvals, gepotidacin for UTI and lenacapavir for treatment and prevention of HIV. You'll hear about outcomes from clinical trials and patient counseling points for the new agents.
Each month, APhA will release two podcast episodes offering a fresh dose of education highlights, practice pearls, and insights to inform your pharmacy practice and advance patient care. Listen to new episodes at your convenience! Both members and nonmembers can log into their APhA pharmacist.com Learning Library account to successfully complete a short assessment at the end of each month to earn 0.5 hours of CE credits (.05 CEU).
Tune in now on our website or subscribe via YouTube, Spotify, or Apple Podcasts.
Disclaimer: The content is intended for informational purposes only and should not be considered or taken as medical advice. The views and opinions expressed in this program are those of the speakers and do not necessarily reflect the opinions or positions of any entities they represent or its employees.
By American Pharmacists Association (APhA)4.1
1111 ratings
In this episode of The First Fill, we will review two recent new drug approvals, gepotidacin for UTI and lenacapavir for treatment and prevention of HIV. You'll hear about outcomes from clinical trials and patient counseling points for the new agents.
Each month, APhA will release two podcast episodes offering a fresh dose of education highlights, practice pearls, and insights to inform your pharmacy practice and advance patient care. Listen to new episodes at your convenience! Both members and nonmembers can log into their APhA pharmacist.com Learning Library account to successfully complete a short assessment at the end of each month to earn 0.5 hours of CE credits (.05 CEU).
Tune in now on our website or subscribe via YouTube, Spotify, or Apple Podcasts.
Disclaimer: The content is intended for informational purposes only and should not be considered or taken as medical advice. The views and opinions expressed in this program are those of the speakers and do not necessarily reflect the opinions or positions of any entities they represent or its employees.

78,608 Listeners

14,465 Listeners

4,806 Listeners

262 Listeners

56,830 Listeners

1,146 Listeners

369,370 Listeners

400 Listeners

728 Listeners

4,789 Listeners

6,561 Listeners

6,428 Listeners

37 Listeners

20,819 Listeners

10,114 Listeners